NewsBite

Sonic Healthcare Limited

ASX Announcements

Change of Director's Interest Notice

Change of Director’s Interest Notice

  • Dec 16, 2024
  • 3 pages

Change of Director's Interest Notice

Change of Director’s Interest Notice

  • Dec 11, 2024
  • 3 pages

Change of Director's Interest Notice

Change of Director’s Interest Notice

  • Dec 11, 2024
  • 3 pages

Change of Director's Interest Notice

Change of Director’s Interest Notice

  • Dec 11, 2024
  • 3 pages

Proposed issue of securities - SHL

Appendix 3B

  • Dec 9, 2024
  • 5 pages

View all SHL announcements

December 2024

Sonic Healthcare chief executive Colin Goldschmidt has made a $700 million investment in Germany.

Sonic Healthcare to buy German lab group for $700m

Pathology giant Sonic Healthcare is buying one of Germany’s top medical lab groups as it seeks to expand its market share in Europe.

  • Michael Smith

June 2024

Aengus Tran, co-founder and CEO Harrison.ai at AFR’s 2024 AI summit.

Sonic Healthcare-backed Harrison.ai boots up $100m-plus Series C raise

Harrison.ai’s management team has commenced discussions with a handful of potential investors regarding the cash call.

  • Sarah Thompson, Kanika Sood and Emma Rapaport
Martin Conlon sees a regime change coming for the Australian market.

What Australia’s great contrarian is buying – and avoiding

Soaring household debt will have ripple effects for ASX investors, according to Schroders’ head of Australian equity, Martin Conlon.

  • Updated
  • James Thomson
Crescent Capital partner and healthcare specialist Daren McKennay has made the firm a bit of money with investments like LifeHealthcare.

Crescent Capital set to take radiology business off The Growth Fund

Crescent Capital, which claims to be the country’s most active private equity manager in healthcare, has secured exclusivity.

  • Sarah Thompson, Kanika Sood and Emma Rapaport

May 2024

Population ageing will increase demand for pathology services.

This routine health test is an investment opportunity

The share prices of pathology companies are below pre-pandemic levels and the world will need more blood tests.

  • Mark Draper
Advertisement

December 2023

<p>

Health, the new frontier for Wesfarmers, Woolworths

Wesfarmers and Woolworths are uniquely positioned to disrupt the health sector by building ecosystems in partnership with insurers and care providers, says Jarden.

  • Sue Mitchell

September 2023

Daniel Moore of IML in Sydney.

What Djokovic taught this fund manager about investing

Daniel Moore aims to be the GOAT of funds management. He’s buying Sonic Healthcare, avoiding iron ore and says the market has missed a trick on a little-known REIT.

  • Joshua Peach

July 2023

The competition regulator has a thing for pathology deals, and the latest one is a doozy.

Pathology dream deal a three-headed competition nightmare

Forget the terms of Australian Clinical Labs’ offer for Healius. What is important is what the regulator says about combining the No.2 and No.3 pathology groups.

  • Updated
  • Anthony Macdonald

June 2023

Infinity Asset Management’s Piers Bolger.

Why this fundie is betting on more M&A action by Sonic Healthcare

Infinity’s Piers Bolger explains why he’s staying away from consumer stocks such as Baby Bunting and City Chic.

  • Joanne Tran

May 2023

Australians over 65 are likely to make up just over a fifth of the population by 2066.

Ways to invest in the Baby Boomer megatrend

With the population over 65 expected to grow at twice the rate of the Australian population, likely winners include healthcare companies and financial services.

  • Mark Draper

April 2023

Street Talk.

Pathology brawl heats up as rivals argue finer points

The trickiest M&A deals are often when two industry players are eyeing each other off, but cannot agree on the terms. That’s what’s going on between the No.2 and No.3 players in the pathology sector.

  • Anthony Macdonald

February 2023

Dr Colin Goldschmidt - CEO of Sonic Healthcare.

Sonic Healthcare shares soar as profit beats pre-pandemic levels

The diagnostic’s company profit was down 54 per cent, but well above pre-pandemic levels, pushing shares to a three-month-high.

  • Tess Bennett

December 2022

Incoming CEO for Healius Maxine Jaquet.

New Healius CEO needs to win back investor trust

The pathology giant is also poised to name a new head of its Lumus Imaging who will start in January.

  • Carrie LaFrenz
Dr Kerryn Phelps (L) and Healius CFO Maxine Jaquet, who is tipped to be named the new CEO of the healthcare group.

Healius CEO poised to step down next year

After five tough years at the helm of the pathology and imaging player, Dr Malcolm Parmenter plans to retire next year.

  • Updated
  • Carrie LaFrenz

November 2022

Microba Life Sciences chairman Ian Frazer, CEO Luke Reid and co-founder Gene Tyson at the listing ceremony in April.

Microba shares soar 55pc after Sonic Healthcare investment

The diagnostics giant has acquired a 19.99 per cent stake in the small-cap biotech and is also seeking approval for another 5 per cent.

  • Yolanda Redrup
Advertisement

August 2022

Sonic Healthcare’s Colin Goldschmidt says the group is always looking at M&A.

COVID will mean more testing for longer: Sonic chief

The healthcare company is on the lookout for deals all the time, says chief executive Colin Goldschmidt.

  • Updated
  • Jemima Whyte

July 2022

Buy, hold, sell: Five stocks battling for blue chip status

Two fund managers take a look at the stocks climbing their way up the index into the ASX 20.

How to pick the right healthcare investments

Longer life expectancy together with the ageing of the global population presents investors with mouth-watering opportunities, but there are plenty of traps.

  • Mark Draper

June 2022

Stephen Ruffels spent almost 15 years at ResMed, before joining Harrison.ai and now he’ll lead its joint venture with Sonic, Franklin.ai.

How Sonic Healthcare and a local AI start-up will shake up pathology

Sonic and Harrison.ai have teamed up to launch Franklin.ai, aiming to speed up the diagnosis and detection of cancer, and other tissue-based diseases.

  • Yolanda Redrup

March 2022

Discretionary stocks have been underlined as key beneficiaries from the budget.

Barrenjoey, Macquarie equity strategists give their budget verdict

Strategists have revealed which corners of the sharemarket will benefit most from the fresh wave of stimulus announced in the federal budget.

  • Updated
  • Alex Gluyas

Original URL: https://www.afr.com/company/shl-1fj